Sangamo Therapeutics (SGMO) Misses Q4 EPS by 8c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $2.04 million versus the consensus estimate of $8.11 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• GE Vernova (GEV) PT Raised to $1,185 at Jefferies
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says